Transcript Cosmo - Investis CMS

MMX™
Multi Matrix System
Presentation
Disclaimer
Important Notice
 For the use of the recipient only. Not to be copied or distributed to any other
person. This presentation has been prepared from publicly available information,
internally developed data and other sources believed to be reliable. No
representation, warranty or undertaking (express or implied) is given and no
responsibility is accepted by Cosmo or by any of its officers, employees or agents
for the completeness or accuracy of any information contained in, or of any
omissions from, this presentation or any supplementary information made
available to any interested party or its advisers, and any liability in respect of such
information or omissions is hereby expressly disclaimed.
 This presentation does not constitute an offer, invitation or recommendation to buy,
2
sell, subscribe for or issue any securities or a solicitation of any such offer or
invitation and shall not form the basis of any contract with Cosmo. Opinions
expressed herein are subject to change without notice. In providing this
presentation, Cosmo undertakes no obligation to provide the recipient with access
to any further information or to correct any inaccuracies or omissions which may
become apparent.
Drug Delivery Platform




3
New oral delivery technology
Designed for off-patent drugs
Focus on inflammatory bowel diseases
Scaleable/low cost of goods
The Drug Delivery Platform
Multi Matrix System™ (MMX ™)
Inert matrix
Hydrophilic
matrix
4
Gastroprotectant layer
LV hydrophilic - amphipatic polymer matrix
HV hydrophilic polym. matrix
inert matrix material
drug (+ excipient)
MMX™ - Release of active ingredient
stomach
Duodenum
Dejunum
%
5
Ileum
Time
Colon
IBD medications: sites of action
MMX™ tablets vs. other dosage forms
Site of action
Oral dosage forms
6
enemas
MMX ™ tablets
1h 30’ small intestine
7h 30’ trasverse colon
7
3h 30’ ileum
10h trasverse colon
4h 30’ ascending colon
15h descending colon
MMX™
8
16h descending colon
24h rectum
MMX™
Low absorption after single dose administration
in Drug (•) and Metabolite (o)
II
Plasma concentration (ng/mL)
10000
9
SI
IL
AC
TC
DC
SC
1000
100
10
1
0
2
4
6
8
10
12
Time (h)
14
16
18
20
22
24